Jul 29, 2022 06:57 PM IST

Hold Sanofi India; target of Rs 6885: ICICI Direct

ICICI Direct recommended hold rating on Sanofi India with a target price of Rs 6885 in its research report dated July 27, 2022.

Buy Sanofi India; target of Rs 8300: Sharekhan

Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 8300 in its research report dated July 26, 2022.

Sanofi India Standalone June 2022 Net Sales at Rs 699.30 crore, down 11.38% Y-o-Y

Hold Sanofi India; target of Rs 7740: ICICI Direct

ICICI Direct recommended hold rating on Sanofi India with a target price of Rs 7740 in its research report dated April 27, 2022.

Buy Sanofi India: target of Rs 9250: Sharekhan

Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 9250 in its research report dated April 26, 2022.

Sanofi India Standalone March 2022 Net Sales at Rs 707.00 crore, down 2.5% Y-o-Y

Sanofi India names Rodolfo Hrosz as new Managing Director

Rodolfo Hrosz will transition from being Sanofi’s General Manager, Consumer Healthcare business in Brazil to his new role in India as soon as the applicable regulatory approvals are in place, Sanofi India said in a statement.

Buy Sanofi India: target of Rs 9250: Sharekhan

Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 9250 in its research report dated March 02, 2022.

Buy Sanofi India; target of Rs 8965: ICICI Direct

ICICI Direct is bullish on Sanofi India recommended buy rating on the stock with a target price of Rs 8965 in its research report dated February 24, 2022.

Sanofi India Standalone December 2021 Net Sales at Rs 687.90 crore, down 4.5% Y-o-Y

Buy Sanofi India: target of Rs 9250: Sharekhan

Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 9250 in its research report dated February 23, 2022.

Sanofi India Standalone September 2021 Net Sales at Rs 754.50 crore, up 9.89% Y-o-Y

Sanofi India Standalone September 2021 Net Sales at Rs 754.50 crore, up 9.89% Y-o-Y

Sanofi India net profit at Rs 530 crore in September quarter

Sanofi India board in its meeting held on July 27 had approved a transaction for slump sale and transfer of its nutraceuticals business to Universal Nutriscience for a consideration of Rs 587 crore.

Universal Medicare-Kedaara Capital consortium completes buyout of Sanofi India’s nutraceutical business

The consortium has appointed Vikash Prasad as the CEO of the business who brings with him over two decades of experience in consumer health across prominent multinational corporations such as GlaxoSmithKline, Sanofi and Abbott.

Buy Sanofi India; target of Rs 9750: ICICI Direct

ICICI Direct is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 9750 in its research report dated July 28, 2021.

Sanofi India share price rises 3% on sale of Nutraceuticals biz to Universal Nutriscience

The company has posted 30.8 percent jump in its June quarter net profit at Rs 178.3 crore against Rs 136.3 crore and revenue was up 11.1% at Rs 789.1 crore versus Rs 710.5 crore, YoY.

Sanofi India Standalone June 2021 Net Sales at Rs 789.10 crore, up 11.06% Y-o-Y

Sanofi India reports Q2 net profit at Rs 178.3 crore

Revenue from operations of the company stood at Rs 789.1 crore for the quarter under consideration.

Universal Medicare-Kedaara Capital consortium emerges as the frontrunner to acquire Sanofi India’s select brands

According to a February 2021 report by Pharma Intelligence , as part of a global drive, Sanofi is looking to sell 150 OTC brands in a radical overhaul of its consumer healthcare operations

Buy Sanofi India: target of Rs 9600: Sharekhan

Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 9600 in its research report dated April 27, 2021.

Sanofi India Standalone March 2021 Net Sales at Rs 725.10 crore, down 7.57% Y-o-Y

Buy Sanofi India: target of Rs 9600: Sharekhan

Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 9600 in its research report dated March 17, 2021.

Buy Sanofi India; target of Rs 9820: ICICI Direct

ICICI Direct is bullish on Sanofi India recommended buy rating on the stock with a target price of Rs 9820 in its research report dated February 24, 2021.

Sanofi India Standalone December 2020 Net Sales at Rs 720.30 crore, down 12.83% Y-o-Y